Literature DB >> 162669

Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis.

T Dürrigl1, M Vitaus, I Pucar, M Miko.   

Abstract

A short-term trial has been performed under double-blind conditions in 50 adult patients with rheumatoid arthritis to compare diclofenac sodium (Voltaren) with both indomethacin and placebo for efficacy and tolerability. The duration of the trial was two weeks and was a between-patient comparison of 25 mg t.i.d. diclofenac sodium, 25 mg t.i.d. indomethacin or placebo using a double-dummy technique. Forty-eight patients completed the trial. In the majority of parameters examined, diclofenac sodium was superior to placebo and indomethacin in therapeutic effect. One patient was withdrawn from the trial because of intolerance to indomethacin and one other because of severe joint pain under indomethacin therapy. Neither active compound caused clinically significant changes in blood picture or urine analysis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 162669     DOI: 10.1177/030006057500300301

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  Which Anti-inflammatory?

Authors:  W G Bensen; M A Bridge
Journal:  Can Fam Physician       Date:  1981-02       Impact factor: 3.275

2.  Adoption of the double dummy trial design to reduce observer bias in testing treatments.

Authors:  Ana Marušić; Stella Fatović Ferenčić
Journal:  J R Soc Med       Date:  2013-05       Impact factor: 5.344

3.  A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents.

Authors:  R E Pemberton; L J Strand
Journal:  Dig Dis Sci       Date:  1979-01       Impact factor: 3.199

4.  The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy.

Authors:  P A Leatham; H A Bird; V Wright; P D Fowler
Journal:  Agents Actions       Date:  1982-04

Review 5.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

6.  International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.

Authors:  D Briancon
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

Review 7.  Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.

Authors:  R N Brogden; R C Heel; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.